Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Parkinson's Disease Research Studies

Study Title:   An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes, Cynapsus)  (Identifier NCT02542696)

Study Purpose:  A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Study Title:   A 15-Week, Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF-06649751 in Subjects with Motor Fluctuations Due to Idiopathic Parkinson’s Disease. (Identifier NCT02687542)

Study Purpose:  The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Study Title: A 15-Week, Phase II, Double-Blind, Randomized, Placebo-Controlled, Flexible Dose Study to Investigate the Efficacy, Safety and Tolerability of PF-06649751 in Subjects with Early Stage Parkinson's Disease. (Identifier NCT02847650)

Study Purpose:  The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721


Study Title:  A Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients. (Identifier NCT02605434)

Study Purpose:  The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor fluctuations such as "off time" in advanced Parkinson's Disease patients.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  For more information email Stephanie Wilson, RN, or call 419.383.6721

Last Updated: 9/12/17